Janx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Janx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Janx Today - Breaking & Trending Today

Janux Therapeutics (NASDAQ:JANX) Coverage Initiated by Analysts at Jonestrading

Jonestrading assumed coverage on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research report released on Tuesday, Benzinga reports. The firm issued a buy rating and a $70.00 price objective on the stock. Other equities analysts also recently issued research reports about the company. Cantor Fitzgerald assumed coverage on Janux Therapeutics in a […] ....

United States , Immunomodulators Tracir , William Blair , Engagers Tractr , Nisa Investment Advisors , China Universal Asset Management Co , Citigroup Inc , Tower Research Capital , Cantor Fitzgerald , Janux Therapeutics Inc , Barclays Plc , Janux Therapeutics , Free Report , Get Free Report , Investment Advisors , Research Capital , Universal Asset Management , Tumor Activatedt Cell Engagers , Tumor Activated Immunomodulators , Janux Therapeutics Daily , Nasdaq Janx , Initiated Coverage ,

Janux Therapeutics (NASDAQ:JANX) Sees Large Volume Increase

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) saw strong trading volume on Wednesday . 1,917,919 shares traded hands during mid-day trading, an increase of 181% from the previous session’s volume of 681,574 shares.The stock last traded at $45.49 and had previously closed at $40.03. Analyst Ratings Changes Several analysts have issued reports […] ....

United States , Engagers Tractr , William Blair , Immunomodulators Tracir , Nisa Investment Advisors , Cantor Fitzgerald , Tower Research Capital , Janux Therapeutics Company Profile , China Universal Asset Management Co , Citigroup Inc , Janux Therapeutics Inc , Barclays Plc , Janux Therapeutics , Get Free Report , Investment Advisors , Research Capital , Universal Asset Management , Tumor Activatedt Cell Engagers , Tumor Activated Immunomodulators , Janux Therapeutics Daily , Nasdaq Janx ,

Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $39.81

Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $39.81, but opened at $41.98. Janux Therapeutics shares last traded at $40.58, with a volume of 45,945 shares. Wall Street Analyst Weigh In Several equities analysts have recently issued reports on the […] ....

William Blair , Immunomodulator Tracir , Tower Research Capital , Janux Therapeutics Inc , Nisa Investment Advisors , China Universal Asset Management Co , Barclays Plc , Citigroup Inc , Janux Therapeutics , Get Free Report , Investment Advisors , Research Capital , Universal Asset Management , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily , Nasdaq Janx ,

Janux Therapeutics' (JANX) "Outperform" Rating Reiterated at Wedbush

Janux Therapeutics (NASDAQ:JANX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by research analysts at Wedbush in a note issued to investors on Monday, RTT News reports. They currently have a $53.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 32.60% from the company’s previous close. Other […] ....

Immunomodulator Tracir , William Blair , Janux Therapeutics Company Profile , Janux Therapeutics Inc , Barclays Plc , China Universal Asset Management Co , Nisa Investment Advisors , Citigroup Inc , Tower Research Capital , Janux Therapeutics , Get Free Report , Investment Advisors , Research Capital , Universal Asset Management , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily , Nasdaq Janx , Reiterated Rating ,

Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasted to Earn FY2028 Earnings of ($1.45) Per Share

Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Analysts at Wedbush issued their FY2028 earnings estimates for shares of Janux Therapeutics in a report issued on Tuesday, February 27th. Wedbush analyst R. Driscoll expects that the company will post earnings per share of ($1.45) for the year. Wedbush has a “Outperform” rating and a $53.00 […] ....

United States , William Blair , Immunomodulator Tracir , American International Group Inc , Charles Schwab Investment Management Inc , Janux Therapeutics Inc , Tower Research Capital , Janux Therapeutics , Free Report , Janux Therapeutic , Schwab Investment Management , Wisconsin Investment Board , International Group , Research Capital , Get Free Report , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily , Nasdaq Janx , Earnings Estimates ,